JP7198670B2 - 免疫調整性ｉｌ２ｒ融合タンパク質およびその使用 - Google Patents

免疫調整性ｉｌ２ｒ融合タンパク質およびその使用 Download PDF

Info

Publication number
JP7198670B2
JP7198670B2 JP2018554677A JP2018554677A JP7198670B2 JP 7198670 B2 JP7198670 B2 JP 7198670B2 JP 2018554677 A JP2018554677 A JP 2018554677A JP 2018554677 A JP2018554677 A JP 2018554677A JP 7198670 B2 JP7198670 B2 JP 7198670B2
Authority
JP
Japan
Prior art keywords
cells
amino acid
host cell
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018554677A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019515672A5 (enExample
JP2019515672A (ja
Inventor
トーマス エム． シュミット，
フィリップ ディー． グリーンバーグ，
インガン エム． ストロムネス，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fred Hutchinson Cancer Center
Original Assignee
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fred Hutchinson Cancer Center filed Critical Fred Hutchinson Cancer Center
Publication of JP2019515672A publication Critical patent/JP2019515672A/ja
Publication of JP2019515672A5 publication Critical patent/JP2019515672A5/ja
Priority to JP2022139098A priority Critical patent/JP2022164858A/ja
Application granted granted Critical
Publication of JP7198670B2 publication Critical patent/JP7198670B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K40/4255—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2018554677A 2016-04-20 2017-04-20 免疫調整性ｉｌ２ｒ融合タンパク質およびその使用 Active JP7198670B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022139098A JP2022164858A (ja) 2016-04-20 2022-09-01 免疫調整性ｉｌ２ｒ融合タンパク質およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662325428P 2016-04-20 2016-04-20
US62/325,428 2016-04-20
PCT/US2017/028693 WO2017184901A1 (en) 2016-04-20 2017-04-20 Immunomodulatory il2r fusion proteins and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022139098A Division JP2022164858A (ja) 2016-04-20 2022-09-01 免疫調整性ｉｌ２ｒ融合タンパク質およびその使用

Publications (3)

Publication Number Publication Date
JP2019515672A JP2019515672A (ja) 2019-06-13
JP2019515672A5 JP2019515672A5 (enExample) 2020-05-28
JP7198670B2 true JP7198670B2 (ja) 2023-01-04

Family

ID=58710057

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018554677A Active JP7198670B2 (ja) 2016-04-20 2017-04-20 免疫調整性ｉｌ２ｒ融合タンパク質およびその使用
JP2022139098A Ceased JP2022164858A (ja) 2016-04-20 2022-09-01 免疫調整性ｉｌ２ｒ融合タンパク質およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022139098A Ceased JP2022164858A (ja) 2016-04-20 2022-09-01 免疫調整性ｉｌ２ｒ融合タンパク質およびその使用

Country Status (7)

Country Link
US (1) US20190127435A1 (enExample)
EP (1) EP3445847B1 (enExample)
JP (2) JP7198670B2 (enExample)
CN (1) CN109312304A (enExample)
CA (1) CA3021455A1 (enExample)
ES (1) ES2981274T3 (enExample)
WO (1) WO2017184901A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201707182WA (en) * 2015-03-05 2017-10-30 Hutchinson Fred Cancer Res Immunomodulatory fusion proteins and uses thereof
US12202856B2 (en) * 2016-05-19 2025-01-21 The General Hospital Corporation Tethered interleukin-2 to its receptor IL-2RBETA, a platform to enhance natural killer and regulatory T cell activity
US11725210B2 (en) 2017-03-17 2023-08-15 Fred Hutchinson Cancer Center Immunomodulatory fusion proteins and uses thereof
CN109503715B (zh) * 2017-09-15 2023-12-15 科济生物医药（上海）有限公司 Il-4r的融合蛋白及其应用
CN108504685A (zh) * 2018-03-27 2018-09-07 宜明细胞生物科技有限公司 一种利用CRISPR/Cas9系统同源重组修复IL-2RG缺陷基因的方法
CN110615843B (zh) * 2018-06-20 2023-05-09 上海隆耀生物科技有限公司 一种包含第三信号受体的嵌合抗原受体及其应用
CN110582515A (zh) * 2018-11-12 2019-12-17 天境生物科技(上海)有限公司 包含cd47抗体和细胞因子的融合蛋白
CA3144549A1 (en) * 2019-06-28 2020-12-30 Cafa Therapeutics Limited Cell for resisting transplant reaction and method
WO2021050752A1 (en) * 2019-09-11 2021-03-18 The Board Of Trustees Of The Leland Stanford Junior University Chimeric orthogonal receptor proteins and methods of use
US20220401537A1 (en) * 2019-09-16 2022-12-22 Fred Hutchinson Cancer Research Center Chimeric receptor proteins and uses thereof
GB201913697D0 (en) * 2019-09-23 2019-11-06 King S College London DAP10/DAP12 fusion polypeptides
WO2021068068A1 (en) * 2019-10-08 2021-04-15 Provincial Health Services Authority Chimeric cytokine receptors
WO2021141986A1 (en) * 2020-01-07 2021-07-15 St. Jude Children's Research Hospital, Inc. Chimeric gmcsf-il18 receptor
CN113249330A (zh) * 2021-05-20 2021-08-13 深圳市先康达生命科学有限公司 免疫细胞及其应用
JP2024542027A (ja) * 2021-11-02 2024-11-13 フレッド ハッチンソン キャンサー センター 細胞標的療法を利用したがんの治療及び関連する研究プロトコル
TW202442689A (zh) 2023-03-03 2024-11-01 美商亞森諾生物科學公司 靶向ｐｓｍａ及ｃａ９之系統
WO2025039159A1 (en) * 2023-08-21 2025-02-27 Hangzhou Hervor Therapeutics Co., Ltd Synthetic cytokine signaling system, preparation method, and uses thereof
WO2025081123A1 (en) 2023-10-12 2025-04-17 Fred Hutchinson Cancer Center Methods and compositions for improving t cell immunotherapy
WO2025085536A1 (en) * 2023-10-16 2025-04-24 Lankenau Institute For Medical Research Biologic conjugates that inhibit production of inflammatory cells and methods of use
CN117511885B (zh) * 2024-01-08 2024-06-11 青岛华赛伯曼医学细胞生物有限公司 提高识别和杀伤肿瘤能力的工程化til细胞及其应用
WO2025245169A1 (en) 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Immunotherapy cells equipped with a collagen-targeting payload

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015513394A (ja) 2012-02-13 2015-05-14 シアトル チルドレンズ ホスピタル ドゥーイング ビジネ 二重特異性キメラ抗原受容体およびその治療的使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
AU695869B2 (en) * 1993-04-06 1998-08-27 Fred Hutchinson Cancer Research Center Chimeric cytokine receptors in lymphocytes
EP1361892A4 (en) * 2001-01-17 2004-10-13 Trubion Pharmaceuticals Inc BINDING DOMAIN FUSION PROTEIN Immunoglobulin
WO2008042814A2 (en) 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
US9272002B2 (en) * 2011-10-28 2016-03-01 The Trustees Of The University Of Pennsylvania Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
WO2014172584A1 (en) * 2013-04-17 2014-10-23 Baylor College Of Medicine IMMUNOSUPPRESSIVE TGF-β SIGNAL CONVERTER

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015513394A (ja) 2012-02-13 2015-05-14 シアトル チルドレンズ ホスピタル ドゥーイング ビジネ 二重特異性キメラ抗原受容体およびその治療的使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LAWRENCE S EVANS; ET AL，EXPRESSION OF CHIMERIC GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR/INTERLEUKIN 2 RECEPTORS IN HUMAN CYTOTOXIC T LYMPHOCYTE CLONES RESULTS IN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR-DEPENDENT GROWTH，HUMAN GENE THERAPY，米国，1999年08月10日，VOL:10, NR:12，PAGE(S):1941 - 1951，http://dx.doi.org/10.1089/10430349950017301

Also Published As

Publication number Publication date
JP2022164858A (ja) 2022-10-27
EP3445847A1 (en) 2019-02-27
CN109312304A (zh) 2019-02-05
US20190127435A1 (en) 2019-05-02
EP3445847B1 (en) 2024-06-05
JP2019515672A (ja) 2019-06-13
ES2981274T3 (es) 2024-10-08
WO2017184901A1 (en) 2017-10-26
CA3021455A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
JP2022164858A (ja) 免疫調整性ｉｌ２ｒ融合タンパク質およびその使用
JP7441201B2 (ja) 免疫調節性融合タンパク質およびその使用
JP7560882B2 (ja) 遺伝子修飾免疫細胞の生存及び増加を特異的に刺激するための方法
US20210277114A1 (en) Car based immunotherapy
JP7696658B2 (ja) ヒトメソセリンを特異的に認識する細胞表面分子、ｉｌ－７、及びｃｃｌ１９を発現する免疫担当細胞
KR102653324B1 (ko) TGFβ 신호 컨버터
JP2024019732A (ja) 免疫調節性融合タンパク質およびその使用
KR102733541B1 (ko) 유전자 치료법
CN111629734A (zh) 用于共刺激的新型平台、新型car设计以及过继性细胞疗法的其他增强
EP3490590A2 (en) Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
KR20180057723A (ko) 항-cd30 키메라성 항원 수용체
CN110257338A (zh) 嵌合细胞因子受体
US20230374454A1 (en) Human immune cells genomically modified to express orthogonal receptors
US20240307536A1 (en) Improved adoptive cell transfer therapy for cancer
JP2024502170A5 (enExample)
CN120882422A (zh) 一种用于治疗血液癌症的试剂盒
CN121693513A (zh) TGFβ转换受体、编码它的核酸、细胞和包含它的药物组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200420

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200420

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210805

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220302

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220527

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220726

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20220826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220901

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221130

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221219

R150 Certificate of patent or registration of utility model

Ref document number: 7198670

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150